Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 349 to 350 of 350 entries
Sorted by: Best Match Show Resources per page
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.

Blood advances

Chihara D, Arons E, Stetler-Stevenson M, Yuan C, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James-Echenique L, Tai CH, Patel KP, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ.
PMID: 34607348
Blood Adv. 2021 Dec 14;5(23):4807-4816. doi: 10.1182/bloodadvances.2021005039.

Hairy cell leukemia variant (HCLv) responds poorly to purine analogue monotherapy. Rituximab concurrent with cladribine (CDAR) improves response rates, but long-term outcomes are unknown. We report final results of a phase 2 study of CDAR for patients with HCLv....

Cite
Chihara D, Arons E, Stetler-Stevenson M, et al. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv. 2021;5(23):4807-4816doi: 10.1182/bloodadvances.2021005039.
Chihara, D., Arons, E., Stetler-Stevenson, M., Yuan, C., Wang, H. W., Zhou, H., Raffeld, M., Xi, L., Steinberg, S. M., Feurtado, J., James-Echenique, L., Tai, C. H., Patel, K. P., Braylan, R. C., Calvo, K. R., Maric, I., Dulau-Florea, A., & Kreitman, R. J. (2021). Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood advances, 5(23), 4807-4816. https://doi.org/10.1182/bloodadvances.2021005039
Chihara, Dai, et al. "Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant." Blood advances vol. 5,23 (2021): 4807-4816. doi: https://doi.org/10.1182/bloodadvances.2021005039
Chihara D, Arons E, Stetler-Stevenson M, Yuan C, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James-Echenique L, Tai CH, Patel KP, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv. 2021 Dec 14;5(23):4807-4816. doi: 10.1182/bloodadvances.2021005039. PMID: 34607348.
Copy Download .nbib Format: NLM
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.

Blood

Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang HW, Wang Y, Inglefield J, Dulau-Florea A, Ceppi F, Hermida LC, Stringaris K, Dunham K, Homan P, Jailwala P, Mirazee J, Robinson W, Chisholm KM, Yuan C, Stetler-Stevenson M, Ombrello AK, Jin J, Fry TJ, Taylor N, Highfill SL, Jin P, Gardner RA, Shalabi H, Ruppin E, Stroncek DF, Shah NN.
PMID: 34525183
Blood. 2021 Dec 16;138(24):2469-2484. doi: 10.1182/blood.2021011898.

Chimeric antigen receptor (CAR) T-cell toxicities resembling hemophagocytic lymphohistiocytosis (HLH) occur in a subset of patients with cytokine release syndrome (CRS). As a variant of conventional CRS, a comprehensive characterization of CAR T-cell-associated HLH (carHLH) and investigations into associated...

Cite
Lichtenstein DA, Schischlik F, Shao L, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021;138(24):2469-2484doi: 10.1182/blood.2021011898.
Lichtenstein, D. A., Schischlik, F., Shao, L., Steinberg, S. M., Yates, B., Wang, H. W., Wang, Y., Inglefield, J., Dulau-Florea, A., Ceppi, F., Hermida, L. C., Stringaris, K., Dunham, K., Homan, P., Jailwala, P., Mirazee, J., Robinson, W., Chisholm, K. M., Yuan, C., Stetler-Stevenson, M., Ombrello, A. K., Jin, J., Fry, T. J., Taylor, N., Highfill, S. L., Jin, P., Gardner, R. A., Shalabi, H., Ruppin, E., Stroncek, D. F., & Shah, N. N. (2021). Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood, 138(24), 2469-2484. https://doi.org/10.1182/blood.2021011898
Lichtenstein, Daniel A, et al. "Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells." Blood vol. 138,24 (2021): 2469-2484. doi: https://doi.org/10.1182/blood.2021011898
Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang HW, Wang Y, Inglefield J, Dulau-Florea A, Ceppi F, Hermida LC, Stringaris K, Dunham K, Homan P, Jailwala P, Mirazee J, Robinson W, Chisholm KM, Yuan C, Stetler-Stevenson M, Ombrello AK, Jin J, Fry TJ, Taylor N, Highfill SL, Jin P, Gardner RA, Shalabi H, Ruppin E, Stroncek DF, Shah NN. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021 Dec 16;138(24):2469-2484. doi: 10.1182/blood.2021011898. PMID: 34525183.
Copy Download .nbib Format: NLM
Showing 349 to 350 of 350 entries